{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-008116","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.889365+00:00","generated_at":"2026-05-15T23:49:29.412085+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Kairos Pharma signs term sheet to acquire two lung cancer assets from Celyn Therapeutics","bullets":["Worldwide rights to CL-273 (pre-IND pan-EGFR inhibitor) and CL-741 (Phase 1-ready c-MET inhibitor) for NSCLC.","No financial terms or expected close date disclosed in press release or filing.","CL-273 is wild-type-sparing with 4-5x wider safety margin; CL-741 targets MET-amplification resistance.","Celyn backed by OrbiMed and Torrey Pines Investment; Kairos plans to use Cedars-Sinai clinical network.","Acquisition aims to address EGFR-mutant and c-MET-driven lung cancer resistance mechanisms."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-008116","json":"https://secwatch.observer/filing/0001493152-26-008116.json","markdown":"https://secwatch.observer/filing/0001493152-26-008116.md","text":"https://secwatch.observer/filing/0001493152-26-008116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000149315226008116/0001493152-26-008116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000149315226008116/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:49:29.412085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}